K

KeyMed Biosciences Inc
HKEX:2162

Watchlist Manager
KeyMed Biosciences Inc
HKEX:2162
Watchlist
Price: 38.2 HKD -3.29% Market Closed
Market Cap: 10.5B HKD
Have any thoughts about
KeyMed Biosciences Inc?
Write Note

KeyMed Biosciences Inc
Other Non-Cash Items

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

KeyMed Biosciences Inc
Other Non-Cash Items Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Non-Cash Items CAGR 3Y CAGR 5Y CAGR 10Y
K
KeyMed Biosciences Inc
HKEX:2162
Other Non-Cash Items
-ÂĄ37.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Other Non-Cash Items
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Other Non-Cash Items
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Other Non-Cash Items
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Other Non-Cash Items
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Imeik Technology Development Co Ltd
SZSE:300896
Other Non-Cash Items
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

KeyMed Biosciences Inc
Glance View

Market Cap
10.7B HKD
Industry
Biotechnology

Keymed Biosciences, Inc. is an investment holding company. The company is headquartered in Chengdu, Sichuan. The company went IPO on 2021-07-08. The firm focuses on the independent discovery and development of innovative biological therapies that address underserved medical needs in the autoimmune and oncology therapeutic areas. The firm has mastered in-house drug discovery and development technologies, including an innovative antibody discovery platform and a proprietary novel T cell engager (nTCE) bispecific antibody platform. The firm has also established a fully integrated platform covering the key functions of biopharmaceutical development. The firm's main products include CM310, CM326 and CMG901.

Intrinsic Value
37.36 HKD
Overvaluation 2%
Intrinsic Value
Price
K

See Also

What is KeyMed Biosciences Inc's Other Non-Cash Items?
Other Non-Cash Items
-37.7m CNY

Based on the financial report for Dec 31, 2023, KeyMed Biosciences Inc's Other Non-Cash Items amounts to -37.7m CNY.

What is KeyMed Biosciences Inc's Other Non-Cash Items growth rate?
Other Non-Cash Items CAGR 1Y
71%

Over the last year, the Other Non-Cash Items growth was 71%.

Back to Top